OPGN / OpGen, Inc. - SEC फाइलिंग, वार्षिक रिपोर्ट, प्रॉक्सी स्टेटमेंट

OPGEN, INC.

Exhibit 21.1 OPGEN, INC. The following is a list of subsidiaries of OpGen, Inc. as of December 31, 2024: Name Jurisdiction of Incorporation CapForce International Holdings Ltd. (“CapForce”) Labuan, Malaysia

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT UNDER SECTIO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-37367 OPGEN, INC. (Exact name of r

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 17, 2025 Date of Report (date of earliest event reported) OpGen, Inc.

LETTER OF ENGAGEMENT FOR US DIRECT LISTING SPONSORSHIP ADVISORY

Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT OPGEN, INC. TREATS AS PRIVATE OR CONFIDENTIAL STRICTLY PRIVATE AND CONFIDENTIAL LETTER OF ENGAGEMENT FOR US DIRECT LISTING SPONSORSHIP ADVISORY Date: 02/01/2024 To: [***] [***] [***] (Hereinafter to be referred to as “Company” o

AGREEMENT OF ASSIGNMENT OF MANDATE IN RESPECT OF DIRECT LISTING SPONSORSHIP ADVISORY SERVICES WITH

Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT OPGEN, INC. TREATS AS PRIVATE OR CONFIDENTIAL AGREEMENT OF ASSIGNMENT OF MANDATE IN RESPECT OF DIRECT LISTING SPONSORSHIP ADVISORY SERVICES WITH [***]. This Assignment of Mandate in respect of US Direct Listing Sponsorship Advis

JOINT VENTURE AGREEMENT

Exhibit 10.3 JOINT VENTURE AGREEMENT This Agreement is made on 3rd April 2025. BETWEEN 1. EUROPEAN CREDIT INVESTMENT BANK (Bank License No. 090099BI), a licensed bank with an office located at Level 6G (2), Main Office Tower, Financial Park Labuan, Jalan Merdeka 87000, Federal Territory of Labuan, Malaysia (hereinafter referred to as “ECIB”); AND 2. CAPFORCE INTERNATIONAL HOLDINGS LTD. (Company No

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 2, 2024 Date of Report (date of earliest event reported) OpGen, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Perio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Pe

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 19, 2024 Date of Report (date of earliest event reported) OpGen, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 4, 2024 Date of Report (date of earliest event reported) OpGen, Inc.

Consulting Agreement

Exhibit 10.1 Consulting Agreement This Consulting Agreement (the “Agreement”) is made and entered into as of December 4, 2024 (the “Effective Date”), by and between OpGen, Inc., a Delaware corporation (the “Company”), and Mohd Azham Azudin as the Chief Operating Officer (the “COO”). The Company and COO may be referred to herein individually as “Party” or collectively, as “Parties.” Recitals Wherea

Consulting Agreement

Exhibit 10.2 Consulting Agreement This Consulting Agreement (the “Agreement”) is made and entered into as of December 4, 2024 (the “Effective Date”), by and between OpGen, Inc., a Delaware corporation (the “Company”), and Gillian Tan Rou Yee as the Company Secretary (the “COSEC”). The Company and COSEC may be referred to herein individually as “Party” or collectively, as “Parties.” Recitals Wherea

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37367 OPGEN,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition P

First Amendment to Securities Purchase Agreement, dated October 3, 2024, by and between the Company and AEI Capital Ltd.

Exhibit 10.1 First Amendment to Securities Purchase Agreement This Securities Purchase Agreement (this “Amendment”) is made and entered into as of October 3, 2024, by and between OpGen, Inc., a Delaware corporation (the “Company”), and AEI Capital Ltd. (the “Purchaser”). Recitals Whereas, the Company and Purchaser entered into that certain Securities Purchase Agreement, dated as of August 22, 2024

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 3, 2024 Date of Report (date of earliest event reported) OpGen, Inc.

Securities Purchase Agreement, dated August 22, 2024, by and between the Company and AEI Capital Ltd.

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 22, 2024 (the “Effective Date”), between OpGen, Inc. a Delaware corporation (the “Company”), and AEI Capital Ltd., whose address is P.O. Box 4342, Road Town, Tortola, BI (the “Purchaser”). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Reg

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 16, 2024 Date of Report (date of earliest event reported) OpGen, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37367 OPGEN, INC.

Financial Statements and Exhibits, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 14, 2024 Date of Report (date of earliest event reported) OpGen, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 9, 2024 Date of Report (date of earliest event reported) OpGen, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 29, 2024 Date of Report (date of earliest event reported) OpGen, Inc.

OPGN / OpGen, Inc. / Lazar David E. - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)1 OpGen, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 68373L406 (CUSIP Nu

Form of Securities Purchase Agreement, dated as of July 30, 2024, by and between David Lazar and AEI Capital Group.

Exhibit 99.2 SECURITIES PURCHASE AGREEMENT This Agreement (the “Agreement”) is entered into as of this 30th day of July 2024 (the “Effective Date”) by and among David Elliot Lazar, whose address is 30B, Tower 200 The Towers, Winston Churchill, San Francisco, Paitilla, Panama City, Panama. 07196 (“Seller”), and AEI Capital Group, whose address is, P.O. Box 4342, Road Town, Tortola, BI (“Purchaser”)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37367 OPGEN, INC

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 5, 2024 Date of Report (date of earliest event reported) OpGen, Inc.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 29, 2024 Date of Report (date of earliest event reported) OpGen, Inc.

Subsidiaries of the Registrant

Exhibit 21.1 OPGEN, INC. The following is a list of subsidiaries of OpGen, Inc. as of December 31, 2023: Name Jurisdiction of Incorporation Curetis GmbH (in insolvency) Germany Ares Genetics GmbH (in insolvency) Austria

Clawback Policy

Exhibit 97.1 OpGen, Inc. Compensation Recoupment Policy 1. Restatement. In the event of any required accounting restatement of the financial statements of OpGen, Inc. (the “Company”) due to the material noncompliance of the Company with any financial reporting requirement under the applicable U.S. federal securities laws, including any required accounting restatement to correct an error in previou

Insider Trading Policy

Exhibit 19 OPGEN, INC. INSIDER TRADING POLICY I. Purpose This Insider Trading Policy (the “Policy”) provides guidelines with respect to transactions in the securities of OpGen, Inc. (the “Company”) and the handling of confidential information about the Company and the companies with which the Company does business. The Company’s Board of Directors has adopted this Policy to promote compliance with

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT UNDER SECTIO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-37367 OPGEN, INC. (Exact name of r

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 25, 2024 Date of Report (date of earliest event reported) OpGen, Inc.

OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q

Exhibit 99.1 OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q ROCKVILLE, Md., May 24, 2024 (GLOBE NEWSWIRE) – OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Quarterly Repo

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 20, 2024 Date of Report (date of earliest event reported) OpGen, Inc.

OpGen Announced 1-for-10 Reverse Stock Split

Exhibit 99.1 OpGen Announced 1-for-10 Reverse Stock Split ROCKVILLE, Md., May 16, 2024 (GLOBE NEWSWIRE) - OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) today announced that the Company’s board of directors has approved a 1-for-10 reverse stock split of its shares of common stock (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. EST on May 20, 2024 and

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 16, 2024 Date of Report (date of earliest event reported) OpGen, Inc.

Amendment Agreement, dated May 16, 2024, by and between OpGen, Inc. and the European Investment Bank

Exhibit 10.1 CLIFFORD CHANCE PARTNERSCHAFT MIT BESCHRÄNKTER BERUFSHAFTUNG Execution Version EUROPEAN INVESTMENT BANK AND OPGEN, INC. AMENDMENT AGREEMENT IN RELATION TO A SETTLEMENT AGREEMENT DATED 25 MARCH 2024 CLIFFORD CHANCE PARTNERSCHAFT MIT BESCHRÄNKTER BERUFSHAFTUNG VON RECHTSANWÄLTEN, STEUERBERA-TERN UND SOLICITORS · SITZ: FRANKFURT AM MAIN · AG FRANKFURT AM MAIN PR 2669 This amendment agree

Certificate of Amendment to the Amended and Restated Certificate of Incorporation of OpGen, Inc., filed with the Secretary of State of the State of Delaware on May 17, 2024

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED OF OPGEN, INC. OpGen, Inc., a corporation duly organized and validly existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”); DOES HEREBY CERTIFY AS FOLLOWS: FIRST: The name of the corporation (the “Corporation”) is: OpGen, Inc. SECOND: The Amended and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Perio

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 9, 2024 Date of Report (date of earliest event reported) OpGen, Inc.

Amendment to the Certificate of Designation of Preferences, Rights and Limitations of Series E Preferred Stock filed with the Secretary of State of the State of Delaware on May 9, 2024

Exhibit 3.2 OPGEN, INC. AMENDED AND RESTATED CERTIFICATE OF DESIGNATIONS, PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES E CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, David Lazar, does hereby certify that: 1. He is the Chief Executive Officer of OpGen, Inc., a Delaware corporation (the “Corporation”). 2. The Corporation is authorized

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 23, 2024 Date of Report (date of earliest event reported) OpGen, Inc.

Letter Agreement, dated April 23, 2024, between OpGen, Inc. and Camtech Pte Ltd

Exhibit 10.1 To: Camtech Pte Ltd 5 Jalan Kilang Barat #01-01 Petro Centre Singapore 159349 April 23, 2024 Dear Meng Han, dear Siew Hwa Based on your email offer dated April 12, 2024, regarding the US Unyvero Business, we would like to propose the following counteroffer: US $218k (will be formally offered to Dr. Volker Danckelmann via the current Curetis GmbH) for all of the existing Unyvero system

OpGen Provides Update on Business Operations and Strategic Opportunities

Exhibit 99.1 OpGen Provides Update on Business Operations and Strategic Opportunities ROCKVILLE, Md., April 29, 2024 (GLOBE NEWSWIRE) – OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it entered into an agreement to sell its commercial customer contracts and installed base of Unyvero systems to Camtech Pte Ltd (“Camtech”), a Singaporean family office for $218,000. The tra

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 22, 2024 Date of Report (date of earliest event reported) OpGen, Inc.

Letter from UHY regarding change in certifying accountant

Exhibit 16.1 April 25, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by OpGen, Inc. under Item 4.01 of its Form 8-K dated April 25, 2024. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of OpGen, Inc. contained therein. Very truly

OPGN / OpGen, Inc. / Lazar David E. - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)1 OpGen, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 68373L406 (CUSIP Nu

OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K

Exhibit 99.1 OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K ROCKVILLE, Md., April 23, 2024 (GLOBE NEWSWIRE) – OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Annual Report on Form

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 18, 2024 Date of Report (date of earliest event reported) OpGen, Inc.

Employment Agreement, dated April 11, 2024, by and between the Company and David Lazar.

Exhibit 10.1 EMPLOYMENT AGREEMENT This Agreement (the “Agreement”), is made and entered into as of April 11, 2024 (the “Agreement Date”), by and between OpGen, Inc. (the “Company”), and David Lazar (the “Executive”, and together with the Company, the “Parties”) NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth below, it is hereby covenanted and agreed by the Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2024 OPGEN, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2024 OPGEN, INC. (Exact name of registrant as specified in its charter) Delaware 001-37367 06-1614015 (State or other jurisdiction of incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive

OPGN / OpGen, Inc. / Lazar David E. - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)1 OpGen, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 68373L406 (CUSIP Nu

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14F-1 INFORMATION STATEMENT Pursuant to Section 14(f) of the Securities Exchange Act of 1934 and Rule 14f-1 thereunder OPGEN, INC. (Name of Registrant as Specified in Its Charter

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14F-1 INFORMATION STATEMENT Pursuant to Section 14(f) of the Securities Exchange Act of 1934 and Rule 14f-1 thereunder OPGEN, INC. (Name of Registrant as Specified in Its Charter) Delaware 001-37367 06-164015 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification

OPGN / OpGen, Inc. / Lazar David E. - SC 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )1 OpGen, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 68373L406 (CUSIP Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 25, 2024 Date of Report (date of earliest event reported) OpGen, Inc. (Exact na

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 25, 2024 Date of Report (date of earliest event reported) OpGen, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Pe

Agreement, dated March 25, 2024, by and between Insolvency Administrator for Curetis GmbH and the Company (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed on March 29, 2024).

Exhibit 10.3 SGP Schnr:icler Gel'wft:1- Restrukturierung KOnigstraBe 18 70173 S1:uttgart Per Mail: [email protected] OpGen Inc. 9717 Key West Avenue Suite 100 Rockville, MD 20850 VEREINIGTE STAATEN SGP Schneider Geiwitz Dr. jur. Volker von Danckelmann Rechtsanwalt T +49 71122 05 48-60 F +49 711 22 OS 48-699 Stuttgart@ schneidergeiwitz.de lnsolvenzverfahren uber das Vermogen der Curetis GmbH, Max-

OpGen Announces Acquisition of Preferred Stock by David Lazar

Exhibit 99.1 OpGen Announces Acquisition of Preferred Stock by David Lazar ● David Lazar invests $3 million in Preferred Stock ● New OpGen Board of Directors appointed ● David Lazar will take over as CEO of OpGen ● OpGen settles outstanding liabilities with EIB ROCKVILLE, Md., March 25, 2024 (GLOBE NEWSWIRE) – OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), announced today that the Company e

Certificate of Designation of Preferences, Rights and Limitations of Series E Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on March 29, 2024).

Exhibit 3.1 Delaware The First State Page 1 I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF DESIGNATION OF “OPGEN, INC.”, FILED IN THIS OFFICE ON THE TWENTY-FIFTH DAY OF MARCH, A.D. 2024, AT 9:38 O’CLOCK A.M. 3338364 8100 Authentication: 203099203 SR# 20241144455 Date: 03-25-24 You may verify this c

Settlement Agreement, dated March 25, 2024, by and between the European Investment Bank and the Company (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed on March 29, 2024).

Exhibit 10.2 CLIFFORD CHANCE PARTNERSCHAFT MIT BESCHRÄNKTER BERUFSHAFTUNG Unterschriftsfassung EUROPEAN INVESTMENT BANK AND OPGEN, INC. SETTLEMENT AGREEMENT IN RELATION TO A GUARANTEE AND INDEMNITY AGREEMENT DATED 9 JULY 2020 CLIFFORD CHANCE PARTNERSCHAFT MIT BESCHRÄNKTER BERUFSHAFTUNG VON RECHTSANWÄLTEN, STEUERBERA-TERN UND SOLICITORS · SITZ: FRANKFURT AM MAIN · AG FRANKFURT AM MAIN PR 2669 This

Form of Director Agreement (incorporated by reference to Exhibit 10.4 to the Registrant’s Current Report on Form 8-K filed on March 29, 2024).

Exhibit 10.4 Execution Version DIRECTOR AGREEMENT DIRECTOR AGREEMENT, dated as of March 25, 2024, by and between OpGen Inc., a Delaware corporation (the “Company”), and David Lazar (the “Director”). W I T N E S S E T H: WHEREAS, the Company wishes to engage the Director and the Director is willing to accept such engagement upon the terms and conditions hereinafter set forth. NOW, THEREFORE, in con

Form of Securities Purchase Agreement, dated as of March 25, 2024, by and between the Company and David Lazar (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on March 29, 2024).

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 25, 2024 (the “Effective Date”), between OpGen, Inc. a Delaware corporation (the “Company”), and Mr. David Lazar, an individual resident in the United Arab Emirates (the “Purchaser” or “Lazar”)). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant

Form of Inducement Offer to Amend Common Stock Purchase Warrants, dated March 26, 2024 (incorporated by reference to Exhibit 10.5 to the Registrant’s Current Report on Form 8-K filed on March 29, 2024).

Exhibit 10.5 OPGEN, INC. March 26, 2024 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Amend Common Stock Purchase Warrants Dear Holder: OpGen, Inc. (the “Company”) is pleased to offer to you the opportunity to amend the warrants to purchase shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), set forth on Exhibit A hereto (the “Existing Warrants”

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 9, 2024 Date of Report (date of earliest event reported) OpGen, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 9, 2024 Date of Report (date of earliest event reported) OpGen, Inc.

Form of Second Amendment Agreement to Warrant Inducement Agreement, by and between the Company and the Holder (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on February 8, 2024).

Exhibit 10.1 OPGEN, INC. 9717 Key West Ave, Suite 100 Rockville, MD 20850 February 7, 2024 To the Holder of February 2018, February 2021, March 2021, October 2021, October 2022, January 2023, and May 2023 Warrants to Purchase Common Stock Re: Amendment to Inducement Offer Letter Dear Holder: Reference is hereby made to that certain inducement offer letter, dated October 12, 2023 (the “Original Ind

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 7, 2024 Date of Report (date of earliest event reported) OpGen, Inc.

Consulting Agreement, dated January 8, 2024, by and between OpGen, Inc. and Albert Weber (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on January 9, 2024).

Exhibit 10.1 9717 Key West Avenue, Suite 100 Rockville, MD 20850 Phone 301-869-9683 Website www.OpGen.com Consultant Name/Entity Albert Weber OpGen Manager Oliver Schacht Effective Date January 8, 2024 CONSULTING AGREEMENT This Consulting Agreement (together with its attachments, this “Agreement”) is entered into and effective as of the date written above (the “Effective Date”) by and between OpGe

Consulting Agreement, dated January 8, 2024, by and between OpGen, Inc. and Johannes Bacher (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed on January 9, 2024).

Exhibit 10.2 9717 Key West Avenue, Suite 100 Rockville, MD 20850 Phone 301-869-9683 Website www.OpGen.com Consultant Name/Entity Johannes Bacher OpGen Manager Oliver Schacht Effective Date January 8, 2024 CONSULTING AGREEMENT This Consulting Agreement (together with its attachments, this “Agreement”) is entered into and effective as of the date written above (the “Effective Date”) by and between O

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 4, 2024 Date of Report (date of earliest event reported) OpGen, Inc. (Exact n

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 4, 2024 Date of Report (date of earliest event reported) OpGen, Inc.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 6, 2023 Date of Report (date of earliest event reported) OpGen, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 4, 2023 Date of Report (date of earliest event reported) OpGen, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 4, 2023 Date of Report (date of earliest event reported) OpGen, Inc.

Termination of a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 20, 2023 Date of Report (date of earliest event reported) OpGen, Inc.

9717 Key West Avenue, Suite 100

Correspondence 9717 Key West Avenue, Suite 100 Rockville, MD 20850 Phone 301-825-6061 Website www.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 14, 2023 Date of Report (date of earliest event reported) OpGen, Inc.

OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update

Exhibit 99.1 OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update · Total revenue for the first nine months of 2023 was approximately $2.35 million compared to approximately $1.89 million in the first nine months of 2022 · Implemented certain cash management initiatives, including restructuring U.S. operations by reducing headcount during the third quarter of 2023 · Sign

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-37367 OPGEN, INC. (Exact name

Calculation of Filing Fee Tables FORM S-1 (Form Type) OPGEN, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) OPGEN, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock underlying Inducement Warrants 457(c) 10,892,728 $0

As filed with the Securities and Exchange Commission on November 13, 2023

As filed with the Securities and Exchange Commission on November 13, 2023 Registration No.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 6, 2023 Date of Report (date of earliest event reported) OpGen, Inc.

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 26, 2023 Date of Report (date of earliest event reported) OpGen, Inc.

Form of Amendment Agreement to Warrant Inducement Agreement, by and between the Company and the Holder

Exhibit 10.1 OPGEN, INC. 9717 Key West Ave, Suite 100 Rockville, MD 20850 October 26, 2023 To the Holder of February 2018, February 2021, March 2021, October 2021, October 2022, January 2023, and May 2023 Re: Amendment to Inducement Offer Letter Dear Holder: Reference is hereby made to that certain inducement offer letter, dated October 12, 2023 (the “Inducement Letter Agreement”), from OpGen, Inc

Form of Warrant Inducement Agreement, by and between the Company and the Holder

Exhibit 10.1 OPGEN, INC. 9717 Key West Ave, Suite 100 Rockville, MD 20850 October 12, 2023 To the Holder of February 2018, February 2021, March 2021, October 2021, October 2022, January 2023, and May 2023 Re: Inducement Offer to Exercise Existing Common Stock Purchase Warrants Dear Holder: OpGen, Inc. (the “Company”) is pleased to offer (this “Inducement Offer”) to you (“Holder”, “you” or similar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 12, 2023 Date of Report (date of earliest event reported) OpGen, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 12, 2023 Date of Report (date of earliest event reported) OpGen, Inc.

Form of Inducement Warrant

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds

Exhibit 99.1 OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds ROCKVILLE, Md., Oct. 12, 2023 (GLOBE NEWSWIRE) - OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that it has entered into an agreement with an inst

321,207 Shares of Common Stock 2,586,207 Series A-1 Warrants to Purchase up to 2,586,207 Shares of Common Stock 2,586,207 Series A-2 Warrants to Purchase up to 2,586,207 Shares of Common Stock 2,265,000 Pre-Funded Warrants to Purchase up to 2,265,000

Filed pursuant to Rule 424(b)(5) Registration No. 333-268648 Prospectus Supplement (To the Prospectus dated January 6, 2023) 321,207 Shares of Common Stock 2,586,207 Series A-1 Warrants to Purchase up to 2,586,207 Shares of Common Stock 2,586,207 Series A-2 Warrants to Purchase up to 2,586,207 Shares of Common Stock 2,265,000 Pre-Funded Warrants to Purchase up to 2,265,000 Shares of Common Stock 7

605,000 Shares of Common Stock 4,495,825 Common Warrants to Purchase 4,495,825 Shares of Common Stock 3,890,825 Pre-Funded Warrants to Purchase 3,890,825 Shares of Common Stock Up to 8,386,650 Shares of Common Stock Underlying the Common Warrants and

Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-271190 Prospectus Supplement (To the Prospectus dated May 1, 2023) 605,000 Shares of Common Stock 4,495,825 Common Warrants to Purchase 4,495,825 Shares of Common Stock 3,890,825 Pre-Funded Warrants to Purchase 3,890,825 Shares of Common Stock Up to 8,386,650 Shares of Common Stock Underlying the Common Warrants and Pre-Funded Warrant

770 Shares of Common Stock issuable upon exercise of Common Warrants

Filed pursuant to Rule 424(b)(5) Registration No. 333-222140 Prospectus Supplement (To the Prospectus dated March 21, 2019) 770 Shares of Common Stock issuable upon exercise of Common Warrants This prospectus supplement updates, supersedes and amends certain information contained in the prospectus dated March 21, 2019 (the “Original Prospectus”) as supplemented by the prospectus supplements dated

150,000 Shares of Preferred Stock 375,000 Warrants to purchase an aggregate of 375,000 Shares of Common Stock (and 750,000 Shares of Common Stock issuable upon the conversion of such Preferred Stock and exercise of such Warrants)

Filed pursuant to Rule 424(b)(5) Registration No. 333-258646 Prospectus Supplement (To the Prospectus dated August 19, 2021) 150,000 Shares of Preferred Stock 375,000 Warrants to purchase an aggregate of 375,000 Shares of Common Stock (and 750,000 Shares of Common Stock issuable upon the conversion of such Preferred Stock and exercise of such Warrants) This prospectus supplement updates, supersede

208,334 Shares of Common Stock Issuable Upon the Exercise of Common Warrants 157,385 Shares of Common Stock Issuable Upon the Exercise of Common Warrants

Filed pursuant to Rule 424(b)(5) Registration No. 333-256820 Prospectus Supplement (To the Prospectus dated June 11, 2021) 208,334 Shares of Common Stock Issuable Upon the Exercise of Common Warrants 157,385 Shares of Common Stock Issuable Upon the Exercise of Common Warrants This prospectus supplement updates, supersedes and amends certain information contained in the prospectus dated June 11, 20

Form of Securities Purchase Agreement, dated October 11, 2023, between OpGen, Inc. and the investor thereto (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on October 11, 2023).

Exhibit 10.1 PREFERRED STOCK PURCHASE AGREEMENT THE PREFERRED SHARES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR THE SECURITIES LAWS OF ANY STATE OR ANY OTHER JURISDICTION. THERE ARE FURTHER RESTRICTIONS ON THE TRANSFERABILITY OF SUCH SECURITIES DESCRIBED HEREIN. This Preferred Stock Purchase Agreement (this “Agreement”), is made as of [], 2023 (the “Effective Date”), by and betwe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 11, 2023 Date of Report (date of earliest event reported) OpGen, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 11, 2023 Date of Report (date of earliest event reported) OpGen, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 6, 2023 Date of Report (date of earliest event reported) OpGen, Inc. (Exact n

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 6, 2023 Date of Report (date of earliest event reported) OpGen, Inc.

Certificate of Designation of Preferences, Rights and Limitations of Series D Preferred Stock

Exhibit 3.1 Opgen, inc. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES D CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE delaware GENERAL CORPORATION LAW The undersigned, Oliver Schacht and Albert Weber, does hereby certify that: 1. He is the President of OpGen, Inc., a Delaware corporation (the “Corporation”). 2. The Corporation is authorized to issue 10,00

9717 Key West Avenue, Suite 100

9717 Key West Avenue, Suite 100 Rockville, MD 20850 Phone 301-869-9683 Website www.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 8, 2023 Date of Report (date of earliest event reported) OpGen, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 8, 2023 Date of Report (date of earliest event reported) OpGen, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 31, 2023 Date of Report (date of earliest event reported) OpGen, Inc. (Exact n

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 31, 2023 Date of Report (date of earliest event reported) OpGen, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-37367 OPGEN, INC. (Exact name of re

OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update

Exhibit 99.1 OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update · Total revenue for the first half of 2023 was approximately $1.65 million, an increase of approximately 15% compared to approximately $1.44 million in the first half of 2022 · Signed FIND R&D collaboration contract extension · Entered distribution agreement with Fisher Healthcare for the distribution of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 10, 2023 Date of Report (date of earliest event reported) OpGen, Inc. (Exact n

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 10, 2023 Date of Report (date of earliest event reported) OpGen, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive

Filing Fee Table

EXHIBIT 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) OPGEN, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, $0.01 par value 457(o) $5,000,000 $0.0001102 $5

As filed with the Securities and Exchange Commission on July 14, 2023

As filed with the Securities and Exchange Commission on July 14, 2023 Registration No.

Standstill Agreement, dated July 4, 2023, by and among Curetis GmbH, as borrower, OpGen, Inc. and Ares Genetics GmbH, as guarantors, and the European Investment Bank, as lender

Exhibit 10.1 Execution Version Curetis GmbH as borrower Certain Companies as Guarantors and European Investment Bank as Bank Standstill AGREEMENT Contents Clause Page 1. Definitions and Interpretation 2 2. Conditions Precedent 4 3. Standstill 4 4. Obligors 5 5. No Waiver 7 6. Termination 7 7. Costs and Expenses 8 8. No Amendments of Finance Documents 8 9. Schedules and Finance Documents 8 10. Amen

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 4, 2023 Date of Report (date of earliest event reported) OpGen, Inc. (Exact name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 4, 2023 Date of Report (date of earliest event reported) OpGen, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 30, 2023 Date of Report (date of earliest event reported) OpGen, Inc. (Exact nam

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 30, 2023 Date of Report (date of earliest event reported) OpGen, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 26, 2023 Date of Report (date of earliest event reported) OpGen, Inc. (Exact nam

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 26, 2023 Date of Report (date of earliest event reported) OpGen, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 5, 2023 Date of Report (date of earliest event reported) OpGen, Inc. (Exact name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 5, 2023 Date of Report (date of earliest event reported) OpGen, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 7, 2023 Date of Report (date of earliest event reported) OpGen, Inc. (Exact name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 7, 2023 Date of Report (date of earliest event reported) OpGen, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive

Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-37367 OPGEN, INC. (Exact name of r

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 15, 2023 Date of Report (date of earliest event reported) OpGen, Inc.

OpGen Reports First Quarter 2023 Financial Results and Provides Business Update

Exhibit 99.1 OpGen Reports First Quarter 2023 Financial Results and Provides Business Update · Total revenue for the first quarter of 2023 was approximately $0.91 million, an increase of approximately 94% compared to the first quarter of 2022 · Expanded U.S. growth opportunities with the Unyvero UTI De Novo FDA submission and Unyvero distribution partnership with Fisher Healthcare · Met all remain

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive

Form of Pre-funded Warrant

Exhibit 4.1 PREFUNDED COMMON STOCK PURCHASE WARRANT OPGEN, Inc. Warrant Shares: Initial Exercise Date: , 2023 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (

Form of Securities Purchase Agreement, dated May 1, 2023, between OpGen, Inc. and the purchaser party thereto

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 1, 2023, between OpGen, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in t

OpGen Announces Pricing of $3.5 Million Public Offering

Exhibit 99.1 OpGen Announces Pricing of $3.5 Million Public Offering ROCKVILLE, MD., May 1, 2023 (GLOBE NEWSWIRE) – OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced the pricing of a public offering of an aggregate of 4,495,825 shares of its common st

Form of Warrant Amendment Agreement, dated May 1, 2023, between OpGen, Inc. and the purchaser party thereto

Exhibit 10.2 May 1, 2023 Holder of Warrants to Purchase Common Stock issued on January 11, 2023, October 3, 2022, October 18, 2021, March 9, 2021, February 9, 2021, February 2, 2018 Re: Amendment to Existing Warrants Dear Holder: Reference is hereby made to the offering on Form S-1 (File No. 333-271190) on or about the date hereof (the “Offering”) by OpGen, Inc. (the “Company”) of its common stock

Form of Common Stock Purchase Warrant

Exhibit 4.2 COMMON STOCK PURCHASE WARRANT OPGEN, INC. Warrant Shares: Issue Date: , 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Stockholder Approval Date (as defined below) (the “In

OpGen Announces Closing of $3.5 Million Public Offering

Exhibit 99.2 OpGen Announces Closing of $3.5 Million Public Offering ROCKVILLE, MD., May 4, 2023 (GLOBE NEWSWIRE) – OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced the closing of its previously announced public offering of an aggregate of 4,495,825

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 1, 2023 Date of Report (date of earliest event reported) OpGen, Inc.

150,000 Shares of Preferred Stock 375,000 Warrants to purchase an aggregate of 375,000 Shares of Common Stock (and 750,000 Shares of Common Stock issuable upon the conversion of such Preferred Stock and exercise of such Warrants)

424B5 1 opgen424b5-258646.htm PROSPECTUS SUPPLEMENT Filed pursuant to Rule 424(b)(5) Registration No. 333-258646 Prospectus Supplement (To the Prospectus dated August 19, 2021) 150,000 Shares of Preferred Stock 375,000 Warrants to purchase an aggregate of 375,000 Shares of Common Stock (and 750,000 Shares of Common Stock issuable upon the conversion of such Preferred Stock and exercise of such War

770 Shares of Common Stock issuable upon exercise of Common Warrants

Filed pursuant to Rule 424(b)(5) Registration No. 333-222140 Prospectus Supplement (To the Prospectus dated March 21, 2019) 770 Shares of Common Stock issuable upon exercise of Common Warrants This prospectus supplement updates, supersedes and amends certain information contained in the prospectus dated March 21, 2019 (the “Original Prospectus”) as supplemented by the prospectus supplement dated S

208,334 Shares of Common Stock Issuable Upon the Exercise of Common Warrants 157,385 Shares of Common Stock Issuable Upon the Exercise of Common Warrants

Filed pursuant to Rule 424(b)(5) Registration No. 333-256820 Prospectus Supplement (To the Prospectus dated June 11, 2021) 208,334 Shares of Common Stock Issuable Upon the Exercise of Common Warrants 157,385 Shares of Common Stock Issuable Upon the Exercise of Common Warrants This prospectus supplement updates, supersedes and amends certain information contained in the prospectus dated June 11, 20

605,000 Shares of Common Stock 4,495,825 Common Warrants up to Purchase 4,495,825 Shares of Common Stock 3,890,825 Pre-Funded Warrants up to Purchase 3,890,825 Shares of Common Stock Up to 8,386,650 Shares of Common Stock Underlying the Common Warran

Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-271190 Prospectus 605,000 Shares of Common Stock 4,495,825 Common Warrants up to Purchase 4,495,825 Shares of Common Stock 3,890,825 Pre-Funded Warrants up to Purchase 3,890,825 Shares of Common Stock Up to 8,386,650 Shares of Common Stock Underlying the Common Warrants and Pre-Funded Warrants We are offering 605,000 shares of our com

321,207 Shares of Common Stock 2,586,207 Series A-1 Warrants to Purchase up to 2,586,207 Shares of Common Stock 2,586,207 Series A-2 Warrants to Purchase up to 2,586,207 Shares of Common Stock 2,265,000 Pre-Funded Warrants to Purchase up to 2,265,000

Filed pursuant to Rule 424(b)(5) Registration No. 333-268648 Prospectus Supplement (To the Prospectus dated January 6, 2023) 321,207 Shares of Common Stock 2,586,207 Series A-1 Warrants to Purchase up to 2,586,207 Shares of Common Stock 2,586,207 Series A-2 Warrants to Purchase up to 2,586,207 Shares of Common Stock 2,265,000 Pre-Funded Warrants to Purchase up to 2,265,000 Shares of Common Stock 7

Form of Securities Purchase Agreement

Exhibit 10.42 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2023, between OpGen, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in this

Form of Common Warrant

EX-4.21 3 ex4x21.htm COMMON STOCK PURCHASE WARRANT Exhibit 4.21 COMMON STOCK PURCHASE WARRANT OPGEN, INC. Warrant Shares: Issue Date: , 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the S

Form of Pre-funded Warrant

Exhibit 4.20 PREFUNDED COMMON STOCK PURCHASE WARRANT OPGEN, Inc. Warrant Shares: Initial Exercise Date: , 2023 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above

As filed with the Securities and Exchange Commission on April 27, 2023

As filed with the Securities and Exchange Commission on April 27, 2023 Registration No.

OpGen, Inc. 9717 Key West Avenue, Suite 100 Rockville, MD 20850

Correspondence OpGen, Inc. 9717 Key West Avenue, Suite 100 Rockville, MD 20850 April 27, 2023 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Conlon Danberg Celeste Murphy Re: OpGen, Inc. Registration Statement on Form S-1, as amended File Number 333-271190 Ladies and Gentlemen: On behalf of OpGen, Inc., (the “Co

Filing Fee Table

EXHIBIT 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) OPGEN, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, $0.01 par value 457(o) $3,500,000.00(3) $0.0

Peter Jaslow

Correspondence Peter Jaslow Tel: 215.864.8737 Fax: 215.864.8999 [email protected] April 27, 2023 By EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Conlon Danberg Celeste Murphy Re: OpGen, Inc. Registration Statement on Form S-1, as amended File Number 333-271190 Ladies and Gentlemen: This letter res

proxy statement for the Annual Meeting of Stockholders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a–6(e)(2)) ☒ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a–6(e)(2)) ☐ Defin

OpGen Enters Into Distribution Agreement for Unyvero in the U.S. with Fisher Healthcare

Exhibit 99.1 OpGen Enters Into Distribution Agreement for Unyvero in the U.S. with Fisher Healthcare - Fisher Healthcare, a part of Thermo Fisher Scientific, will become the non-exclusive national laboratory distribution partner alongside OpGen, Inc.’s direct sales in the U.S. for the Unyvero A50 platform - Initial focus on FDA cleared Unyvero LRT (BAL) cartridges for hospitalized pneumonia patien

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 18, 2023 Date of Report (date of earliest event reported) OpGen, Inc. (Exact na

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 18, 2023 Date of Report (date of earliest event reported) OpGen, Inc.

OpGen Submits De Novo request to the U.S. FDA for Unyvero Urinary Tract Infection Panel

Exhibit 99.1 OpGen Submits De Novo request to the U.S. FDA for Unyvero Urinary Tract Infection Panel · Based on large multi-center study with over 1,800 patient samples · Primary endpoint for Unyvero UTI for urinary tract infection was successfully met and shows overall weighted average sensitivity of 96.8% and overall weighted average specificity of 97.4% · Submission follows FDA’s De Novo pathwa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 18, 2023 Date of Report (date of earliest event reported) OpGen, Inc. (Exact na

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 18, 2023 Date of Report (date of earliest event reported) OpGen, Inc.

Filing Fee Table

EXHIBIT 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) OPGEN, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Maximum Aggregate Offering Price(1) Amount of Registration Fee Fees to Be Paid Equity Common Stock, $0.01 par value 457(o) $10,000,000 $1,102.00 Total Offer

As filed with the Securities and Exchange Commission on April 7, 2023

As filed with the Securities and Exchange Commission on April 7, 2023 Registration No.

OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Exhibit 99.1 OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update · Total revenue for 2022 was approximately $2.6 million · Balance sheet strengthened by recently closed public offering with gross proceeds of $7.5 million · Conference call to be held March 29, 2023 at 4:30 p.m. ET ROCKVILLE, Md., March 29, 2023 (GLOBE NEWSWIRE) - OpGen, Inc. (Nasdaq: OPGN,

Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-37367 OPGEN, INC. (Exact name of r

Subsidiaries of the Registrant

Exhibit 21.1 OPGEN, INC. The following is a list of subsidiaries of OpGen, Inc. as of December 31, 2022: Name Jurisdiction of Incorporation Curetis GmbH Germany Ares Genetics GmbH Austria

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 29, 2023 Date of Report (date of earliest event reported) OpGen, Inc. (Exact na

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 29, 2023 Date of Report (date of earliest event reported) OpGen, Inc.

OpGen, Inc. Consolidated Balance Sheets

Exhibit 99.2 OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update · Total revenue for 2022 was approximately $2.6 million · Balance sheet strengthened by recently closed public offering with gross proceeds of $7.5 million · Conference call to be held March 29, 2023 at 4:30 p.m. ET ROCKVILLE, Md., March 30, 2023 (GLOBE NEWSWIRE) - OpGen, Inc. (Nasdaq: OPGN,

Non-Employee Director Compensation Policy

Exhibit 10.3 Non-Employee Director Compensation Policy Cash Compensation: Non-Employee Director Annual Retainer (other than chair): $25,000 Board Chair: $75,000 Audit Committee member: $7,000 Audit Committee Chair: $15,000 Compensation Committee member: $6,000 Compensation Committee Chair: $12,000 All other committee membership: $3,500 All other committee Chair: $7,500 Equity Compensation: Initial

Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to Exhibit 4.23 to the Registrant’s Annual Form 10-K filed on March 30, 2023)

Exhibit 4.23 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of the securities of OpGen Inc. (the “Company,” “we,” “us” and “our”) that are registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). This description

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 14, 2023 Date of Report (date of earliest event reported) OpGen, Inc. (Exact na

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 14, 2023 Date of Report (date of earliest event reported) OpGen, Inc.

OpGen Announces Exercise of All Prefunded Warrants

Exhibit 99.1 OpGen Announces Exercise of All Prefunded Warrants ROCKVILLE, MD., February 17, 2023 (GLOBE NEWSWIRE) – OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced that all of the prefunded warrants that were issued in its public offering that clos

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 17, 2023 Date of Report (date of earliest event reported) OpGen, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 17, 2023 Date of Report (date of earliest event reported) OpGen, Inc.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 20, 2023 Date of Report (date of earliest event reported) OpGen, Inc.

Letter from CohnReznick regarding change in certifying accountant

Exhibit 16.1 January 20, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated January 20, 2023 of OpGen, Inc. and are in agreement with the statements contained therein. /s/ CohnReznick LLP

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 19, 2023 Date of Report (date of earliest event reported) OpGen, Inc.

OpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business Update

Exhibit 99.1 OpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business Update - Preliminary full year revenue for 2022 of approximately $2.7 million is within most recent guidance range - Cash position as of December 31, 2022 was approximately $7.4 million - Balance sheet strengthened by recently closed public offering with gross proceeds of $7.5 million ROCKVILLE, MD., January 18, 202

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 18, 2023 Date of Report (date of earliest event reported) OpGen, Inc.

OpGen Announces Pricing of $7.5 Million Public Offering

Exhibit 99.1 OpGen Announces Pricing of $7.5 Million Public Offering ROCKVILLE, MD., January 6, 2023 (GLOBE NEWSWIRE) – OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced the pricing of a public offering of an aggregate of 2,586,207 shares of its commo

OpGen Announces Closing of $7.5 Million Public Offering

Exhibit 99.2 OpGen Announces Closing of $7.5 Million Public Offering ROCKVILLE, MD., January 11, 2023 (GLOBE NEWSWIRE) – OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced the closing of its previously announced public offering of an aggregate of 2,586

321,207 Shares of Common Stock 2,586,207 Series A-1 Warrants to Purchase up to 2,586,207 Shares of Common Stock 2,586,207 Series A-2 Warrants to Purchase up to 2,586,207 Shares of Common Stock 2,265,000 Pre-Funded Warrants to Purchase up to 2,265,000

Filed Pursuant to rule 424(b)(3) Registration Statement No. 333-268648 Prospectus 321,207 Shares of Common Stock 2,586,207 Series A-1 Warrants to Purchase up to 2,586,207 Shares of Common Stock 2,586,207 Series A-2 Warrants to Purchase up to 2,586,207 Shares of Common Stock 2,265,000 Pre-Funded Warrants to Purchase up to 2,265,000 Shares of Common Stock 7,437,414 Shares of Common Stock Underlying

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 6, 2023 Date of Report (date of earliest event reported) OpGen, Inc. (Exact n

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 6, 2023 Date of Report (date of earliest event reported) OpGen, Inc.

Form of Pre-funded Warrant

Exhibit 4.20 PREFUNDED COMMON STOCK PURCHASE WARRANT OPGEN, Inc. Warrant Shares: Initial Exercise Date: , 2023 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above

Filing Fee Table

EXHIBIT 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) OPGEN, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, $0.01 par value 457(o) $10,000,000.00(3) $0.

January 5, 2023

CORRESP 1 filename1.htm Correspondence January 5, 2023 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: OpGen, Inc. Registration Statement on Form S-1 (Registration No. 333-268648) - Concurrence in Acceleration Request Ladies and Gentlemen: H.C. Wainwright & Co., LLC (“Wainwright”), solely acting as placement agent on a best-eff

Form of Series A-1 and Series A-2 Warrants

Exhibit 4.21 EXHIBIT A-2 SERIES [A-1] [A-2] COMMON STOCK PURCHASE WARRANT OPGEN, INC. Warrant Shares: Initial Exercise Date: , 2023 THIS SERIES [A-1] [A-2] COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or a

As filed with the Securities and Exchange Commission on January 5, 2023

As filed with the Securities and Exchange Commission on January 5, 2023 Registration No.

OpGen, Inc. 9717 Key West Avenue, Suite 100 Rockville, MD 20850

CORRESP 1 filename1.htm Correspondence OpGen, Inc. 9717 Key West Avenue, Suite 100 Rockville, MD 20850 January 5, 2023 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Sean Healy Dorrie Yale Re: OpGen, Inc. Registration Statement on Form S-1, as amended File Number 333-268648 Ladies and Gentlemen: On behalf of OpG

Form of Securities Purchase Agreement

Exhibit 10.55 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of , 2023, between OpGen, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions set forth in this

Certificate of Amendment to the Amended and Restated Certificate of Incorporation of OpGen, Inc., filed with the Secretary of the State of Delaware on January 4, 2023 (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on January 4, 2023)

EX-3.1 2 ex3x1.htm EXHIBIT 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Exhibit 3.1

OpGen Announced 1-for-20 Reverse Stock Split

EX-99.1 3 ex99x1.htm EXHIBIT 99.1 Exhibit 99.1 OpGen Announced 1-for-20 Reverse Stock Split ROCKVILLE, MD., January 4, 2023 (GLOBE NEWSWIRE) – OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced that the Company’s board of directors has approved a 1-for

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 4, 2023 Date of Report (date of earliest event reported) OpGen, Inc.

Mary J. Mullany

CORRESP 1 filename1.htm Correspondence Mary J. Mullany Tel: 215.864.8631 Fax: 215.864.8999 [email protected] December 30, 2022 By EDGAR Division of Corporation Finance Office of Industrial Applications and Services United States Securities and Exchange Commission Washington, D.C. 20549 Attn: Sean Healy Dorrie Yale Re: OpGen, Inc. Registration Statement on Form S-1 Filed December 1, 2022 Fil

As filed with the Securities and Exchange Commission on December 30, 2022

As filed with the Securities and Exchange Commission on December 30, 2022 Registration No.

Peter Jaslow

CORRESP 1 filename1.htm Correspondence Peter Jaslow Tel: 215.864.8737 Fax: 215.864.8999 [email protected] December 21, 2022 By EDGAR Division of Corporation Finance Office of Industrial Applications and Services United States Securities and Exchange Commission Washington, D.C. 20549 Attn: Sean Healy Dorrie Yale Re: OpGen, Inc. Registration Statement on Form S-1 Filed December 1, 2022 File N

December 16, 2022

CORRESP 1 filename1.htm Correspondence Peter Jaslow Tel: 215.864.8737 Fax: 215.864.8999 [email protected] December 16, 2022 By EDGAR Division of Corporation Finance Office of Industrial Applications and Services United States Securities and Exchange Commission Washington, D.C. 20549 Attn: Sean Healy Dorrie Yale Re: OpGen, Inc. Registration Statement on Form S-1 Filed December 1, 2022 File N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 13, 2022 Date of Report (date of earliest event reported) OpGen, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 13, 2022 Date of Report (date of earliest event reported) OpGen, Inc.

OpGen Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel

Exhibit 99.1 OpGen Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel · Study has enrolled over 1,800 patient samples at 4 U.S. clinical trial sites · Primary endpoint for Unyvero UTI for urinary tract infection shows overall weighted average sensitivity of 96.4% and overall weighted average specificity of 97.4% in preliminary analysis · Clinical perform

Filing Fee Table

EX-FILING FEES 3 ex107.htm CALCULATION OF FILING FEE TABLES EXHIBIT 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) OPGEN, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Maximum Aggregate Offering Price(1) Amount of Registration Fee Fees to Be Paid Equity Common Sto

As filed with the Securities and Exchange Commission on December 1, 2022

As filed with the Securities and Exchange Commission on December 1, 2022 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 30, 2022 Date of Report (date of earliest event reported) OpGen, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 30, 2022 Date of Report (date of earliest event reported) OpGen, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37367 OPGEN,

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 8, 2022 Date of Report (date of earliest event reported) OpGen, Inc.

OpGen Reports Third Quarter 2022 Financial Results and Provides Business Update

Exhibit 99.1 OpGen Reports Third Quarter 2022 Financial Results and Provides Business Update ? Completes first two commercial customer installations for Acuitas AMR Gene Panel ? OpGen subsidiary, Curetis, signed collaboration agreement with BioVersys AG and R&D collaboration agreement with FIND for the Unyvero A30 RQ platform ? Elects Yvonne Schlaeppi as new, independent non-executive director to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEF 14A 1 opgendef14a.htm DEFINITIVE 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as per

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive

Form of Pre-Funded Common Stock Purchase Warrant.

Exhibit 4.2 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT opgen, inc. Warrant Shares: Initial Exercise Date: October 3, 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the dat

Form of Common Stock Purchase Warrant.

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Form of Securities Purchase Agreement, dated September 30, 2022, by and between OpGen, Inc. and the Investor.

Exhibit 10.1 FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of September 30, 2022 between OpGen, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions

OpGen Announces Closing of $3.38 Million Registered Direct Offering

Exhibit 99.2 OpGen Announces Closing of $3.38 Million Registered Direct Offering ROCKVILLE, Md., Oct. 3, 2022 (GLOBE NEWSWIRE) - OpGen, Inc. (Nasdaq: OPGN, ?OpGen? or the ?Company?), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced that it has closed its previously announced registered direct offering w

OpGen Announces $3.38 Million Registered Direct Offering

Exhibit 99.1 OpGen Announces $3.38 Million Registered Direct Offering ROCKVILLE, Md., Sept. 30, 2022 (GLOBE NEWSWIRE) - OpGen, Inc. (Nasdaq: OPGN, ?OpGen? or the ?Company?), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced that it has entered into a securities purchase agreement with a single institutio

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 30, 2022 Date of Report (date of earliest event reported) OpGen, Inc.

5,360,000 Shares of Common Stock 33,810 Shares of Preferred Stock 4,300,000 Shares of Common Stock Underlying Pre-funded Warrants

424B5 1 opgen424b5-258646.htm 424B5 Filed pursuant to Rule 424(b)(5) Registration No. 333-258646 Prospectus Supplement (To the Prospectus dated August 19, 2021) 5,360,000 Shares of Common Stock 33,810 Shares of Preferred Stock 4,300,000 Shares of Common Stock Underlying Pre-funded Warrants We are offering (i) 5,360,000 shares of our common stock, par value $0.01 per share, or the Common Shares, (i

Certificate of Designation of Preferences, Rights and Limitations of Series C Mirroring Preferred Stock

Exhibit 3.1 Opgen, inc. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C MIRRORING PREFERRED STOCK PURSUANT TO SECTION 151 OF THE delaware GENERAL CORPORATION LAW The undersigned, Oliver Schacht, does hereby certify that: 1. He is the President of OpGen, Inc., a Delaware corporation (the ?Corporation?). 2. The Corporation is authorized to issue 10,000,000 shares of pre

Form of Warrant Amendment Agreement, dated September 30, 2022, by and between OpGen, Inc. and the Investor.

Exhibit 10.2 September 30, 2022 Holder of Warrants to Purchase Common Stock issued on October 18, 2021, March 9, 2021, February 9, 2021, February 2, 2018 Re: Amendment to Existing Warrants Dear Holder: Reference is hereby made to the offering on or about the date hereof (the ?Offering?) by OpGen, Inc. (the ?Company?) of its common stock, par value $0.01 per share (?Common Stock?) (collectively, th

150,000 Shares of Preferred Stock 7,500,000 Warrants to purchase an aggregate of 7,500,000 Shares of Common Stock (and 15,000,000 Shares of Common Stock issuable upon the conversion of such Preferred Stock and exercise of such Warrants)

Filed pursuant to Rule 424(b)(5) Registration No. 333-258646 Prospectus Supplement (To the Prospectus dated August 19, 2021) 150,000 Shares of Preferred Stock 7,500,000 Warrants to purchase an aggregate of 7,500,000 Shares of Common Stock (and 15,000,000 Shares of Common Stock issuable upon the conversion of such Preferred Stock and exercise of such Warrants) This prospectus supplement updates, su

Up to $3,500,000 of Common Stock ___________________

Filed pursuant to Rule 424(b)(5) Registration No. 333-258646 Prospectus Supplement (To the Prospectus dated August 19, 2021) Up to $3,500,000 of Common Stock This prospectus supplement updates and amends certain information contained in the prospectus supplement dated June 24, 2022 (the ?Original Supplement?), to the prospectus dated August 19, 2021 (the ?Base Prospectus? and, together with the Or

15,385 Shares of Common Stock issuable upon exercise of Common Warrants

424B5 1 opgen333-222140.htm 424B5 Filed pursuant to Rule 424(b)(5) Registration No. 333-222140 Prospectus Supplement (To the Prospectus dated March 21, 2019) 15,385 Shares of Common Stock issuable upon exercise of Common Warrants This prospectus supplement updates, supersedes and amends certain information contained in the prospectus dated March 21, 2019 (the “Original Prospectus”), relating to up

4,166,666 Shares of Common Stock Issuable Upon the Exercise of Common Warrants 3,147,700 Shares of Common Stock Issuable Upon the Exercise of Common Warrants

424B5 1 opgen424b5-256820.htm 424B5 Filed pursuant to Rule 424(b)(5) Registration No. 333-256820 Prospectus Supplement (To the Prospectus dated June 11, 2021) 4,166,666 Shares of Common Stock Issuable Upon the Exercise of Common Warrants 3,147,700 Shares of Common Stock Issuable Upon the Exercise of Common Warrants This prospectus supplement updates, supersedes and amends certain information conta

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 20, 2022 Date of Report (date of earliest event reported) OpGen, Inc.

OpGen Subsidiary Curetis and FIND Sign R&D Collaboration Agreement for Unyvero A30 RQ Platform

Exhibit 99.1 OpGen Subsidiary Curetis and FIND Sign R&D Collaboration Agreement for Unyvero A30 RQ Platform ? FIND, the global alliance for diagnostics, together with German KfW bank co-funds development of Unyvero A30 RQ platform for low and middle income countries (LMICs) ? Initial project focuses on feasibility study for the rapid detection of antimicrobial resistance (AMR) markers from blood c

Nasdaq Grants OpGen 180-Day Extension to Meet Minimum Bid Price Requirement

Exhibit 99.1 Nasdaq Grants OpGen 180-Day Extension to Meet Minimum Bid Price Requirement ROCKVILLE, Md., August 31, 2022 - OpGen, Inc. (Nasdaq: OPGN, ?OpGen?), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that it has received written notification from the Listing Qualification Department of The NASDAQ

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 30, 2022 Date of Report (date of earliest event reported) OpGen, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37367 OPGEN, INC.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 11, 2022 Date of Report (date of earliest event reported) OpGen, Inc.

OpGen Reports Second Quarter 2022 Financial Results and Provides Business Update

Exhibit 99.1 OpGen Reports Second Quarter 2022 Financial Results and Provides Business Update ? Total Q2 2022 revenues of $1.0 million with product sales a key growth driver ? First two commercial customer contracts for Acuitas AMR Gene Panel signed in June and July 2022 ? Requested additional 180-day period to regain compliance with Nasdaq minimum bid price rule ? Management conference call sched

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 8, 2022 Date of Report (date of earliest event reported) OpGen, Inc.

OpGen Announces Preliminary Unaudited Revenue and Cash Position for Second Quarter 2022 and Provides Business Update

Exhibit 99.1 OpGen Announces Preliminary Unaudited Revenue and Cash Position for Second Quarter 2022 and Provides Business Update ? Preliminary Total Revenue for Q2 2022 was approximately $1.0 million ? Cash as of June 30, 2022 was approximately $16.6 million ? First commercial customer contract for Acuitas AMR Gene Panel signed in June 2022 ROCKVILLE, Md., July 8, 2022 (GLOBE NEWSWIRE) - OpGen, I

At the Market Offering Agreement, dated June 24, 2022, by and between OpGen, Inc. and H.C. Wainwright & Co., LLC (incorporated by reference to Exhibit 1.1 to the Registrant’s Current Report on Form 8-K filed on June 24, 2022).

Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT June 24, 2022 H.C. Wainwright & Co., LLC 430 Park Avenue New York, NY 10022 Ladies and Gentlemen: OpGen, Inc., a corporation organized under the laws of Delaware (the ?Company?), confirms its agreement (this ?Agreement?) with H.C. Wainwright & Co., LLC (the ?Manager?) as follows: 1. Definitions. The terms that follow, when used in this Agreement and any

Up to $10,650,000 of Common Stock

Filed pursuant to Rule 424(b)(5) Registration No. 333-258646 Prospectus Supplement (To the Prospectus dated August 19, 2021) Up to $10,650,000 of Common Stock We have entered into an at-the-market common stock sales agreement, or the Sales Agreement, dated June 24, 2022, with H.C. Wainwright & Co., LLC, or the Sales Agent, as sales agent relating to the offer and sale of the shares of our common s

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 17, 2022 Date of Report (date of earliest event reported) OpGen, Inc.

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 9, 2022 Date of Report (date of earliest event reported) OpGen, Inc.

As filed with the Securities and Exchange Commission on June 3, 2022

As filed with the Securities and Exchange Commission on June 3, 2022 Registration No.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) OpGen, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.01 per s

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) OpGen, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.01 per s

As filed with the Securities and Exchange Commission on June 3, 2022

As filed with the Securities and Exchange Commission on June 3, 2022 Registration No.

Form of Inducement Award Grant Agreement.

EX-10.1 3 ex10x1.htm FORM OF INDUCEMENT AWARD GRANT AGREEMENT. Exhibit 10.1 Employee Stock Option Award Agreement Granted Under OpGen, Inc. 2022 INDUCEMENT GRANT STOCK OPTION PLAN 1.Grant of Option. This certificate evidences a stock option (this “Stock Option”) granted by OpGen, Inc., a Delaware corporation (the “Company”), on January 3, 2022 (the “Grant Date”), to (the “Holder”), pursuant to the

2022 Inducement Stock Option Grant Plan.

EX-10.2 4 ex10x2.htm 2022 INDUCEMENT STOCK OPTION GRANT PLAN. Exhibit 10.2 OPGEN, INC. 2022 INDUCEMENT GRANT STOCK OPTION PLAN ARTICLE 1 ADMINISTRATION 1.1 Effective Date. This 2022 Inducement Grant Stock Option Plan (this “Plan”) became effective on January 3, 2022. The Plan will terminate upon the expiration or termination of the last outstanding award. 1.2 Administration. The Compensation Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEFA14A 1 opgendefa14a060122.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permi

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 23, 2022 Date of Report (date of earliest event reported) OpGen, Inc.

Waiver and Amendment Letter, dated May 23, 2022

EX-10.1 2 ex10x1.htm WAIVER AND AMENDMENT LETTER, DATED MAY 23, 2022 Exhibit 10.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37367 OPGEN, INC

OpGen Reports First Quarter 2022 Financial Results and Provides Business Update

Exhibit 99.1 OpGen Reports First Quarter 2022 Financial Results and Provides Business Update ? Total Q1 2022 revenues of $0.5 million ? Cash position of approximately $30.7 million to reach into Q1-2023 ? Management conference call scheduled for May 12, 2022, at 4:30 p.m. EDT ROCKVILLE, Md., May 12th, 2022 (GLOBE NEWSWIRE) ? OpGen, Inc. (Nasdaq: OPGN, ?OpGen? or ?the Company?), a precision medicin

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 12, 2022 Date of Report (date of earliest event reported) OpGen, Inc.

OpGen’s Subsidiary Curetis and European Investment Bank Plan to Restructure Debt Repayment

Exhibit 99.1 OpGen?s Subsidiary Curetis and European Investment Bank Plan to Restructure Debt Repayment ROCKVILLE, Md., April 25, 2022 - OpGen, Inc. (Nasdaq: OPGN, ?OpGen?), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that its subsidiary, Curetis GmbH (?Curetis?), and the European Investment Bank (EIB

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Defin

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 25, 2022 Date of Report (date of earliest event reported) OpGen, Inc.

Definitive Proxy Statement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

PRE 14A 1 opgnpre14a.htm PRELIMINARY 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (

Subsidiaries of the Registrant

EX-21.1 3 ex21x1.htm EXHIBIT 21.1 Exhibit 21.1 OPGEN, INC. The following is a list of subsidiaries of OpGen, Inc. as of December 31, 2021: Name Jurisdiction of Incorporation AdvanDx, Inc. Delaware OpGen A/S Denmark Crystal GmbH Germany Curetis GmbH Germany Curetis USA Delaware Ares Genetics GmbH Austria

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ?ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ?TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-37367 OPGEN, INC. (Exact name of reg

Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

Exhibit 4.19 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of the securities of OpGen Inc. (the ?Company,? ?we,? ?us? and ?our?) that are registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). This description

OpGen Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Exhibit 99.1 OpGen Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update ? Total revenue for 2021 was approximately $4.3 million ? Strong total cash position of approximately $36.1 million as of December 31, 2021, up significantly from $13.4 million at year-end 2020 ? Conference call to be held March 29, 2022 at 4:30 p.m. EDT ROCKVILLE, Md., March 29th, 2022 (GLO

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 29, 2022 Date of Report (date of earliest event reported) OpGen, Inc.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 28, 2022 Date of Report (date of earliest event reported) OpGen, Inc.

OpGen Announces Preliminary Unaudited Revenue for Fiscal 2021 and Provides Business Update

Exhibit 99.1 OpGen Announces Preliminary Unaudited Revenue for Fiscal 2021 and Provides Business Update ? Preliminary unaudited revenue for 2021 was approximately $4.3 million ? Maintained strong balance sheet with $36.1 million cash as of December 31, 2021 and total capital raised in 2021 of $51.2 million ? Conversion of all 150,000 preferred shares into 7.5 million common shares completed by inv

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 10, 2022 Date of Report (date of earliest event reported) OpGen, Inc.

Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 8, 2021 Date of Report (date of earliest event reported) OpGen, Inc.

OpGen Announces Results of Special Meeting of Stockholders

Exhibit 99.1 OpGen Announces Results of Special Meeting of Stockholders ROCKVILLE, Md., December 8, 2021 ? OpGen, Inc. (Nasdaq: OPGN, ?OpGen? or the ?Company?), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, today announced that stockholders have approved the two proposals voted on at the Company?s Special Meeting of St

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 30, 2021 Date of Report (date of earliest event reported) OpGen, Inc.

OpGen Subsidiary Ares Genetics Announces Strategic Database Access Transaction

EX-99.1 2 opgenex99z1.htm PRESS RELEASE EXHIBIT 99.1 OpGen Subsidiary Ares Genetics Announces Strategic Database Access Transaction - Ares Genetic is granting a permanent, unrestricted and non-exclusive access to a small subset of the proprietary ARESdb data asset to an unnamed global corporation and leader in microbiology and infectious disease diagnostics. - The transaction with a one-time fee f

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37367 OPGEN, I

OpGen Reports Third Quarter 2021 Financial Results and Provides Business Update

EX-99.1 2 ex99x1.htm EXHIBIT 99.1 Exhibit 99.1 OpGen Reports Third Quarter 2021 Financial Results and Provides Business Update · Total Revenue for Q3 2021 was approximately $1.2 million · Cash as of September 30, 2021, was approximately $25.4 million, up significantly from the $13.4 million at year-end 2020 · Cash balance was further strengthened significantly by $15 million financing completed in